Microvessels form the blood-brain barrier, a network that regulates molecular transfer between the vasculature and brain parenchyma. In cerebral small vessel disease (SVD), a leading cause of stroke ...

Even as two amyloid immunotherapies are in clinical use, scientists still have many questions about how these antibodies affect the brain. Neuropathology and biomarker data from treated patients are ...

More than two decades have passed since William Pardridge of the University of California, Los Angeles, used the analogy of a Trojan horse to describe molecular transport shuttles that can sneak ...

reactive to aa 1-16 of Aβ and to APP; reacts to the abnormally processed isoforms, as well as precursor forms ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

In older women, brief suspensions of respiration during sleep (apnea) may cause more than daytime drowsiness, increased cardiovascular risk, and insulin resistance—it may also lead to mild cognitive ...

Time to rewrite the brain anatomy textbook? In addition to the outermost dura, middle arachnoid, and innermost pia membranes surrounding the brain, researchers led by Kjeld Møllgård, University of ...

In a draft decision, the CMS proposed covering Aduhelm only in clinical trials. Most Alzheimer’s researchers support the proposal. Some challenged its practicality. The manufacturers of the other anti ...